Nivolumab (Opdivo) 40/100/120mg | BMS China Originator | GLT

Generic Information: Opdivo (China)

Opdivo is the originator brand of nivolumab, developed and marketed by Bristol-Myers Squibb (BMS). This China-sourced presentation is available in three single-dose vial strengths — 40 mg/4 mL, 100 mg/10 mL and 120 mg/12 mL — all formulated as a 10 mg/mL solution for intravenous infusion. Nivolumab is a PD-1 immune-checkpoint inhibitor approved for a broad range of solid tumours and blood cancers, and it is reimbursed under China's national medical insurance for several key indications.

What Is Nivolumab (Opdivo) Used For?

Nivolumab is approved for many cancers because it works on the immune system rather than on a single tumour type. Its indications include melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch-repair-deficient colorectal cancer, hepatocellular carcinoma, oesophageal cancer and gastric cancer. It is used both as a single agent and in combination with other therapies such as ipilimumab or chemotherapy, depending on the disease.

How Does Nivolumab Work?

Nivolumab is a human IgG4 monoclonal antibody that binds to the PD-1 receptor on T cells. PD-1 is an immune checkpoint that cancer cells exploit to switch off the body's anti-tumour immune response — by engaging PD-1 through the ligands PD-L1 and PD-L2, tumours escape detection. Nivolumab blocks this interaction, releasing the brake on T cells so the immune system can recognise and attack cancer cells again. This is why a single medicine can be effective across many different tumour types.

Indications

The approved indications span melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-H/dMMR colorectal cancer, hepatocellular carcinoma, oesophageal cancer, gastric cancer and malignant pleural mesothelioma. Treatment should be initiated and supervised by an oncologist experienced in immunotherapy, and biomarker testing such as PD-L1 expression or MSI/MMR status guides use in several indications.

Dosage

Nivolumab is given by intravenous infusion over 30 minutes. The standard single-agent schedule is 240 mg every two weeks or 480 mg every four weeks. The three vial strengths — 40 mg, 100 mg and 120 mg — allow flexible dose preparation while minimising drug waste. In combination regimens the dose and schedule vary by indication, and treatment continues until disease progression or unacceptable toxicity.

Side Effects

The most common side effects are fatigue, rash, musculoskeletal pain, diarrhoea, itching and nausea. Because nivolumab activates the immune system, it can also cause immune-mediated reactions affecting the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands, kidneys and skin. These require prompt recognition and may need corticosteroid treatment or discontinuation. Patients should report new cough, diarrhoea, yellowing of the skin, unusual fatigue or skin changes without delay.

Storage

Opdivo is a refrigerated medicine that must be stored and handled by a healthcare facility. Vials should be kept refrigerated and protected from light, and prepared by trained staff for intravenous infusion. Patients receive the treatment in a clinic or hospital setting under medical supervision.

Why Choose Opdivo Through GLT?

For overseas patients and institutions, sourcing nivolumab through GLT provides access to a genuine BMS originator product from the China market, where medical-insurance coverage and local pricing can offer meaningful savings. GLT supports cold-chain logistics for this refrigerated biologic and ships from a Hong Kong-licensed facility with full documentation.

How to Order

To order Opdivo (nivolumab) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and cold-chain delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is Opdivo given at home or in hospital? Nivolumab is an intravenous infusion given over 30 minutes in a clinic or hospital, not a self-administered medicine.

What are the available vial sizes? This China-market product comes in 40 mg/4 mL, 100 mg/10 mL and 120 mg/12 mL single-dose vials, all at 10 mg/mL.

How is the dose given? The standard single-agent schedule is 240 mg every two weeks or 480 mg every four weeks.